

# Enantioselective Aldol Cyclodehydrations Catalyzed by Antibody 38C2


Benjamin List, Richard A. Lerner,\* and Carlos F. Barbas III\*

Skaggs Institute for Chemical Biology and the Department of Molecular Biology,  
The Scripps Research Institute, 10550 North Torrey Pines Road,  
La Jolla, California 92037

carlos@scripps.edu

Received March 26, 1999

## ABSTRACT



Aldolase antibody 38C2 catalyzes the enantioselective aldol cyclodehydration of 4-substituted-2,6-heptanediones (**3**) to give enantiomerically enriched 5-substituted-3-methyl-2-cyclohexen-1-ones (**4**). Yields, enantioselectivities, and product purities are markedly increased compared to the L-proline-catalyzed reactions.

Enantioselective reactions typically rely on the differentiation between the two enantiotopic faces of an sp<sup>2</sup> carbon center. Most often this center is connected to an oxygen, a nitrogen, or another carbon atom via a double bond. Examples include the asymmetric dihydroxylation (AD)<sup>1</sup> and the catalytic enantioselective hydrogenation of olefins.<sup>2</sup> A different type of enantioselectivity is observed in reactions where two enantiotopic groups are differentiated (Figure 1). Despite a few known small molecule catalysts,<sup>3</sup> natural enzymes dominate this reaction class. Examples include the esterase-

catalyzed *meso*-diesters and the reverse reaction, the lipase-catalyzed desymmetrization of *meso*-diols.<sup>4</sup>

While catalytic antibodies have been shown to be efficient catalysts for the enantioface-differentiating reactions<sup>5</sup> and enantiomer-differentiating kinetic resolutions,<sup>6</sup> enantiogroup-differentiating reactions with catalytic antibodies have rarely been reported.<sup>7</sup> In this paper we demonstrate the use of aldolase antibody 38C2 for the enantiogroup-differentiating aldol cyclodehydration of 4-substituted-2,6-heptanediones (**3**) to give enantiomerically enriched 5-substituted-3-methyl-2-cyclohexen-1-ones (**4**).

Aldolase antibody 38C2 (Aldrich no. 47,995-0) has been shown to be a highly efficient *and* enantioselective catalyst




Figure 1.

(1) Johnson, R. A.; Sharpless, K. B. In *Catalytic Asymmetric Synthesis*; Ojima, I., Ed.; VCA: Weinheim, 1993; pp 227–272.

(2) Takaya, H.; Ohta, T.; Noyori, R., ref 1, pp 1–39.

(3) For example, see: Vedejs, E.; Chen, X. *J. Am. Chem. Soc.* **1996**, *118*, 1809–1810.

(4) Wallace, J. S.; Baldwin, B. W.; Morrow, C. J. *J. Org. Chem.* **1992**, *57*, 5231–5239.


(5) See, for example: (a) Hsieh, L. C.; Yonkovich, S.; Kochersperger, L.; Schultz, P. G. *Science* **1993**, *260*, 337. (b) Reymond, J.-L.; Janda, K. D.; Lerner, R. A. *J. Am. Chem. Soc.* **1992**, *114*, 2257. See ref 9a.

(6) Janda, K. D.; Shevlin, C. G.; Lerner, R. A. *Science* **1993**, *259*, 490. See also ref 9b.

(7) Ikeda, S.; Weinhouse, M. I.; Janda, K. D.; Lerner, R. A. *J. Am. Chem. Soc.* **1991**, *113*, 7763–7764. See also ref 13.


for both aldol and *retro*-aldol reactions with rate accelerations approaching those of natural aldolase enzymes.<sup>8</sup> Furthermore, and in contrast to its natural counterparts, this antibody is a broad scope aldol catalyst that has been shown to work with over 200 different substrate combinations.<sup>9</sup> We have used antibody 38C2 in the enantioselective synthesis of naturally occurring pheromone derivatives,<sup>10</sup> deoxy-sugars,<sup>11</sup> and in a total synthesis of epothilone A.<sup>12</sup> Furthermore, we demonstrated its use in a preparative scale synthesis of the Wieland–Miescher ketone (**2**) from achiral triketone **1** (Scheme 1).<sup>13</sup> Traditionally, this reaction is catalyzed by

Scheme 1



L-proline.<sup>14</sup> However, here the product is obtained with an ee of 71%. A related transformation that has been catalyzed by L-proline is the enantioselective cyclodehydration of 4-substituted-2,6-heptanediones (**3**) to the 5-substituted-3-methyl-2-cyclohexen-1-ones (**4**) (Scheme 2).<sup>15</sup> Stereochemi-

Scheme 2



cally, both reactions are enantioselective and probably occur via an enamine mechanism. However, in the


former case (**1** → **2**) the enantiodifferentiation follows enamine formation, while in the latter case (**3** → **4**) enantiodifferentiation occurs upon enamine formation.

In the L-proline-catalyzed reaction, typically low yields and enantioselectivities are observed.

We found that antibody 38C2 catalyzes the cyclodehydration of **3** (R = H) quite efficiently with  $k_{\text{cat}} = 0.082 \text{ min}^{-1}$ ,  $K_M = 2 \text{ mM}$ , and  $k_{\text{cat}}/k_{\text{uncat}} = 1.2 \times 10^7$ .<sup>9a</sup> The question was whether antibody 38C2 was capable of catalyzing this transformation with enantioselectivity when provided with substrates **3** where R ≠ H.

For the synthesis of the starting 1,5-diketones **3a–c**, we followed a route that has been developed by Sakurai and co-workers.<sup>16</sup> Thus, Lewis acid mediated conjugate addition of allyltrimethylsilane to  $\alpha,\beta$ -unsaturated ketones **5a–c** gave olefins **6a–c**.<sup>17</sup> Wacker oxidation of  $\delta,\epsilon$ -unsaturated ketones **6a–c** then furnished diketones **3a–c**.<sup>18</sup> Interestingly, we found that the Wacker oxidation did not require an oxygen atmosphere. Simple stirring under air furnished the products in equivalent yield.<sup>19</sup> Racemic reference compounds **4a–c** can be prepared by base treatment (KOH/MeOH) of ketones **3a–c** (Scheme 3).<sup>20</sup>

Scheme 3



The results of the antibody-catalyzed cyclization of diketones **3** are shown in Scheme 4.

(8) (a) Wagner, J.; Lerner, R. A.; Barbas, C. F., III. *Science* **1995**, *270*, 1797. (b) Barbas, C. F., III; Heine, A.; Zhong, G.; Hoffmann, T.; Gramatikova, S.; Björnstedt, R.; List, B.; Anderson, J.; Stura, E. A.; Wilson, I. A.; Lerner, R. A. *Science* **1997**, *278*, 2085–2092.

(9) (a) Hoffmann, T.; Zhong, G.; List, B.; Shabat, D.; Anderson, J.; Gramatikova, S.; Lerner, R. A.; Barbas, C. F., III. *J. Am. Chem. Soc.* **1998**, *120*, 2768–2779. (b) Zhong, G.; Shabat, D.; List, B.; Anderson, J.; Sinha, S. C.; Lerner, R. A.; Barbas, C. F., III. *Angew. Chem., Int. Ed. Engl.* **1998**, *37*, 2481–2484. (c) List, B.; Barbas, C. F., III; Lerner, R. A. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *15351*–15355.

(10) List, B.; Shabat, D.; Barbas, C. F., III; Lerner, R. A. *Chem. Eur. J.* **1998**, *4*, 881–885.

(11) Shabat, D.; List, B.; Lerner, R. A.; Barbas, C. F., III. *Tetrahedron Lett.* **1999**, *40*, 1437–1440.

(12) Sinha, S. C.; Barbas, C. F., III; Lerner, R. A. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *14603*–14608.

(13) Zhong, G.; Hoffmann, T.; Lerner, R. A.; Danishefsky, S.; Barbas, C. F., III. *J. Am. Chem. Soc.* **1997**, *119*, 8131–8132.

(14) (a) Eder, U.; Sauer, G.; Wiechert, R. *Angew. Chem., Int. Ed. Engl.* **1971**, *10*, 496–497. (b) Hajos, Z. G.; Parrish, D. R. *J. Org. Chem.* **1974**, *39*, 1615–1621.

(15) Agami, C.; Platzer, N.; Sevestre, H. *Bull. Soc. Chim. Fr.* **1987**, *2*, 358–360.


(16) Hosomi, A.; Kobayashi, H.; Sakurai, H. *Tetrahedron Lett.* **1980**, *21*, 955–958.

(17) Hosomi, A.; Sakurai, H. *J. Am. Chem. Soc.* **1977**, *99*, 1673–1675. The yield of olefin **6c** was diminished from concurrent cyclobutane formation. A similar observation has been made by Hosomi et al. (ref 16).

(18) Tsuji, J.; Shimizu, I.; Yamamoto, K. *Tetrahedron Lett.* **1976**, *2975*–2976.

(19) Doron Shabat, The Scripps Research Institute, personal communication.

Scheme 4



(S)-4	R	ee
<b>a</b>	Ph	42%
<b>b</b>	<i>n</i> -C <sub>5</sub> H <sub>11</sub>	46%
<b>c</b>	<i>p</i> AcNHC <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> CH <sub>2</sub>	62%


Antibody 38C2 (10  $\mu$ M, 2 mol %) catalyzes the cyclodehydration of diketones **3a-c** (500  $\mu$ M in phosphate buffered saline (PBS), pH 7.4, 10% CH<sub>3</sub>CN) very efficiently to give the (S)-configured products **4a-c** with yields generally exceeding 95%.

The enantioselectivity of these reactions is moderate to good. The ee's were determined by chiral-phase HPLC analysis.<sup>21</sup>

To determine the absolute configuration of enones **4a-c**, we used the products from the L-proline-catalyzed reaction as a reference standard. This transformation is known to give the corresponding (R)-isomers (Scheme 5).

All products obtained from the L-proline-catalyzed reactions had a configuration opposite that of the products produced in the antibody-catalyzed reaction as determined

Scheme 5



(R)-4	R	ee
<b>a</b>	Ph	47%
<b>b</b>	<i>n</i> -C <sub>5</sub> H <sub>11</sub>	20%
<b>d</b>	Me	42%
<b>e</b>	<i>i</i> Pr	8%
<b>f</b>	<i>t</i> Bu	0%

} ref. 15

by chiral-phase HPLC analyses.<sup>20</sup> Interestingly, and in contrast to these results, in the Wieland–Miescher case both L-proline and 38C2 gave the same enantiomer.

In summary, aldolase antibody 38C2 has been shown to be an efficient catalyst for the enantioselective cyclodehydration of 4-substituted 2,6-heptanediones. The observed enantioselectivities are modest in comparison to the exceptional high ee's that are usually obtained in aldol additions and *retro*-aldol reactions catalyzed by antibody 38C2.<sup>9a,b</sup> However, product yields, purities, and to some extent enantioselectivities are far better than those obtained from the corresponding L-proline-catalyzed reactions.

**Acknowledgment.** This study was supported in part by the NIH (CA27489). B.L. thanks the Alexander von Humboldt Stiftung, Germany, for a Feodor Lynen fellowship.

OL9905405

(20) All new compounds gave satisfactory spectroscopic data (<sup>1</sup>H and <sup>13</sup>C NMR and HRMS).

(21) **4a** and **4b**: Chiracell ODR, 60% H<sub>2</sub>O (0.1% TFA), 40% CH<sub>3</sub>CN, 0.6 mL/min. **4c**: Chiracell ODR, 70% H<sub>2</sub>O (0.1% TFA), 30% CH<sub>3</sub>CN, 0.6 mL/min. (S)-**4a** 46.5 min, (R)-**4a** 49.0 min; (S)-**4b** 51.8 min, (R)-**4b** 50.7 min; (S)-**4c** 48.2 min, (R)-**4c** 45.0 min.

